Albany Molecular Research, Inc. (AMRI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Albany Molecular Research, Inc. (AMRI) trades at $21.74 with AI Score 49/100 (Grade C). Albany Molecular Research, Inc. (AMRI) operates as a contract research and manufacturing organization, providing services to the pharmaceutical and biotechnology industries. Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for AMRI: AMRI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMRI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMRI: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Albany Molecular Research, Inc. (AMRI) Healthcare & Pipeline Overview
Albany Molecular Research, Inc. (AMRI) is a contract development and manufacturing organization (CDMO) providing drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies. AMRI supports clients from early research to commercial production, focusing on integrated solutions and specialized capabilities within the pharmaceutical services sector.
What Is the Investment Thesis for AMRI?
Investing in AMRI requires careful consideration of its financial performance and market dynamics. The company's negative P/E ratio of -13.15 and negative profit margin of -12.3% indicate current profitability challenges. However, its gross margin of 23.3% suggests potential for improvement with better cost management and operational efficiencies. A beta of 1.04 indicates market correlation. Growth catalysts include expanding its CDMO services, strategic acquisitions, and increasing demand for outsourced pharmaceutical services. Key risks involve intense competition, regulatory changes, and the cyclical nature of the pharmaceutical industry. The investment thesis hinges on AMRI's ability to improve profitability, capitalize on growth opportunities, and manage risks effectively.
Based on FMP financials and quantitative analysis
AMRI Key Highlights
- P/E ratio of -13.15 indicates the company is currently not profitable.
- Profit margin of -12.3% reflects challenges in cost management and operational efficiency.
- Gross margin of 23.3% shows potential for profitability improvement with better cost control.
- Beta of 1.04 suggests the stock's price movements are similar to the overall market.
- No dividend yield indicates that the company is not currently returning profits to shareholders.
Who Are AMRI's Competitors?
AMRI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RWMBX American Funds Washington Mutual R2 | $65.64 | +0.17% | $147B | 46 |
| CAIBX American Funds Capital Income Builder Class A | $83.28 | +0.59% | $128B | 44 |
| PEQSX Putnam Large Cap Value Fund | $44.01 | -0.41% | $52.6B | 47 |
| SCIOX Columbia Seligman Technology and Information Fund Advisor Class | $133.48 | +0.56% | $11.6B | 44 |
| TLYIX Nuveen Lifecycle Index 2035 R6 | $32.49 | -0.15% | $11.0B | 44 |
| SHAPX ClearBridge Appreciation A | $36.95 | +0.35% | $9.58B | 44 |
| FDFIX Fidelity Flex 500 Index Fund | $31.51 | -1.19% | $9.04B | 44 |
| JGMIX Janus Henderson Triton Fund | $27.39 | +0.18% | $5.92B | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMRI's Key Strengths?
- Comprehensive suite of services from drug discovery to commercial manufacturing
- Experienced team of scientists and engineers
- Global footprint with facilities in North America, Europe, and Asia
- Focus on building long-term partnerships with clients
What Are AMRI's Weaknesses?
- Negative P/E ratio and profit margin indicate current profitability challenges
- Dependence on a limited number of large clients
- Exposure to regulatory changes and compliance requirements
- Potential for competition from larger CDMOs with greater resources
What Could Drive AMRI Stock Higher?
- Potential for strategic acquisitions to expand service offerings and geographic reach within the next 1-2 years.
- Increasing demand for outsourced pharmaceutical services driving revenue growth over the next 5-10 years.
- Expansion of CDMO services to capture a larger share of the growing market within the next 2-3 years.
What Are the Key Risks for AMRI?
- Negative return on equity (-23.9%) — the business is not currently generating profit on shareholder capital.
- Intense competition from other CDMOs and in-house capabilities of pharmaceutical companies.
- Regulatory changes and compliance requirements impacting operations and costs.
- Economic downturns and global health crises affecting demand for pharmaceutical services.
- Dependence on a limited number of large clients, creating revenue concentration risk.
What Are the Growth Opportunities for AMRI?
- Expanding CDMO Services: AMRI can grow by expanding its range of CDMO services, including specialized capabilities such as sterile fill-finish and complex chemistry. The global CDMO market is projected to reach $227.34 billion by 2028, growing at a CAGR of 6.4% from 2021. By investing in new technologies and expanding its service offerings, AMRI can capture a larger share of this growing market. This expansion can occur within the next 2-3 years.
- Strategic Acquisitions: AMRI can pursue strategic acquisitions to expand its geographic reach, enhance its service offerings, and gain access to new technologies. The pharmaceutical services industry is consolidating, with larger CDMOs acquiring smaller players to expand their capabilities and market presence. AMRI can target companies with complementary expertise or geographic presence to accelerate its growth and improve its competitive positioning. These acquisitions could be completed within the next 1-2 years.
- Increasing Demand for Outsourced Pharmaceutical Services: The increasing demand for outsourced pharmaceutical services presents a significant growth opportunity for AMRI. Pharmaceutical companies are increasingly outsourcing their research and manufacturing activities to reduce costs, improve efficiency, and focus on their core competencies. AMRI can capitalize on this trend by offering integrated solutions and building long-term partnerships with its clients. This is an ongoing trend expected to continue for the next 5-10 years.
- Focus on Specialty Pharmaceutical Products: AMRI can focus on developing and manufacturing specialty pharmaceutical products, such as orphan drugs and biosimilars, which offer higher margins and less competition. The market for specialty pharmaceutical products is growing rapidly, driven by increasing prevalence of chronic diseases and the development of new therapies. AMRI can leverage its scientific expertise and manufacturing capabilities to develop and manufacture these products for its clients. This focus can be implemented over the next 3-5 years.
- Leveraging Technological Advancements: AMRI can leverage technological advancements, such as artificial intelligence and automation, to improve its efficiency, reduce costs, and enhance its service offerings. AI can be used to accelerate drug discovery, optimize manufacturing processes, and improve quality control. Automation can reduce labor costs and improve productivity. By investing in these technologies, AMRI can gain a competitive advantage and improve its profitability. These advancements can be integrated over the next 2-4 years.
What Opportunities Does AMRI Have?
- Expanding CDMO services to capture a larger share of the growing market
- Pursuing strategic acquisitions to expand geographic reach and service offerings
- Capitalizing on the increasing demand for outsourced pharmaceutical services
- Focusing on specialty pharmaceutical products with higher margins and less competition
What Threats Does AMRI Face?
- Intense competition from other CDMOs and in-house capabilities of pharmaceutical companies
- Cyclical nature of the pharmaceutical industry and fluctuations in R&D spending
- Potential for product liability claims and recalls
- Economic downturns and global health crises
What Are AMRI's Competitive Advantages?
- Scientific Expertise: AMRI has a team of experienced scientists and engineers with expertise in drug discovery, development, and manufacturing.
- Integrated Solutions: AMRI offers a comprehensive suite of services from early-stage research to commercial production, providing a one-stop-shop for its clients.
- Global Footprint: AMRI operates multiple facilities across North America, Europe, and Asia, allowing it to serve a global client base.
- Long-Term Partnerships: AMRI focuses on building long-term partnerships with its clients, ensuring recurring revenue and strong relationships.
What Does AMRI Do?
Albany Molecular Research, Inc. (AMRI) was founded in 1991 to provide chemistry services to the pharmaceutical industry. Over the years, AMRI has evolved from a pure chemistry provider to a full-service contract development and manufacturing organization (CDMO). The company offers a range of services including drug discovery, development, and manufacturing for both small and large molecule therapeutics. AMRI supports pharmaceutical and biotechnology companies from early-stage research through commercial production. Its services include medicinal chemistry, custom synthesis, process development, analytical services, and sterile fill-finish services. AMRI operates multiple facilities across North America, Europe, and Asia, allowing it to serve a global client base. The company focuses on providing integrated solutions, leveraging its scientific expertise and manufacturing capabilities to accelerate drug development timelines and reduce costs for its clients. AMRI's competitive positioning lies in its ability to offer a comprehensive suite of services, from drug discovery to commercial manufacturing, making it a valuable partner for pharmaceutical and biotechnology companies seeking to outsource their research and manufacturing needs.
What Products and Services Does AMRI Offer?
- Provides drug discovery services, including medicinal chemistry and custom synthesis.
- Offers drug development services, such as process development and analytical services.
- Manufactures active pharmaceutical ingredients (APIs) for pharmaceutical companies.
- Provides sterile fill-finish services for injectable drugs.
- Offers integrated solutions from early-stage research to commercial production.
- Supports both small and large molecule therapeutics.
How Does AMRI Make Money?
- Generates revenue by providing contract research and manufacturing services to pharmaceutical and biotechnology companies.
- Charges fees for its services based on project scope, complexity, and timelines.
- Focuses on building long-term partnerships with its clients to ensure recurring revenue.
- Invests in research and development to expand its service offerings and improve its capabilities.
What Industry Does AMRI Operate In?
AMRI operates in the pharmaceutical services industry, which is characterized by increasing demand for outsourced research and manufacturing services. The global CDMO market is expected to grow due to factors such as rising R&D spending by pharmaceutical companies, increasing complexity of drug development, and the need for specialized manufacturing capabilities. AMRI competes with other CDMOs, as well as in-house research and manufacturing capabilities of large pharmaceutical companies. The company's success depends on its ability to offer competitive pricing, high-quality services, and innovative solutions to meet the evolving needs of its clients.
Who Are AMRI's Key Customers?
- Pharmaceutical companies seeking to outsource their research and manufacturing activities.
- Biotechnology companies developing new therapies.
- Generic drug manufacturers looking for API sourcing and manufacturing support.
- Virtual pharmaceutical companies without internal research and manufacturing capabilities.
ROE -24%Key Financial Metrics
Return on equity for Albany Molecular Research, Inc. stands at -23.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.8%, showing how much profit it generates from its asset base. A current ratio of 2.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.6%, the inverse of the P/E and a quick read on earnings relative to price.
How Albany Molecular Research, Inc. Is Valued
Relative to its peer group, AMRI's quantitative score of 49/100 is roughly in line with the peer average of 45/100.
AMRI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Comprehensive suite of services from drug discovery to commercial manufacturing
- Experienced team of scientists and engineers
- Global footprint with facilities in North America, Europe, and Asia
- Focus on building long-term partnerships with clients
Bear Case
- Negative P/E ratio and profit margin indicate current profitability challenges
- Dependence on a limited number of large clients
- Exposure to regulatory changes and compliance requirements
- Potential for competition from larger CDMOs with greater resources
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AMRI Latest News
No recent news available for AMRI.
AMRI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMRI.
Price Targets
Wall Street price target analysis for AMRI.
AMRI MoonshotScore
What does this score mean?
The MoonshotScore rates AMRI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Pharmaceutical ServicesAlbany Molecular Research, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for AMRI?
AMRI holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Albany Molecular Research, Inc. (AMRI) operates as a contract research and manufacturing organization, providing services to the pharmaceutical and biotechnology industries. The company specializes …
What does Albany Molecular Research, Inc. do?
Albany Molecular Research, Inc. (AMRI) is a contract development and manufacturing organization (CDMO) that provides a comprehensive suite of services to the pharmaceutical and biotechnology industries. These services span from early-stage drug discovery, including medicinal chemistry and custom synthesis, to drug development, manufacturing of active pharmaceutical ingredients (APIs), and sterile fill-finish services for injectable drugs.
What do analysts say about AMRI stock?
Given the absence of current analyst ratings, it's important to consider the company's fundamentals. AMRI's negative P/E ratio and profit margin suggest profitability challenges, while its gross margin indicates potential for improvement. The company's growth prospects are tied to its ability to expand its CDMO services, pursue strategic acquisitions, and capitalize on the increasing demand for outsourced pharmaceutical services.
What are the main risks for AMRI?
AMRI faces several key risks, including intense competition from other CDMOs and the in-house capabilities of pharmaceutical companies. Regulatory changes and compliance requirements can impact its operations and costs. Economic downturns and global health crises can affect the demand for pharmaceutical services. Additionally, the company's dependence on a limited number of large clients creates revenue concentration risk.
What are the key factors to evaluate for AMRI?
Albany Molecular Research, Inc. (AMRI) holds an AI score of 49/100 (low). Not financial advice.
How frequently does AMRI data refresh on this page?
AMRI's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AMRI's recent stock price performance?
Albany Molecular Research, Inc. (AMRI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive suite of services from drug discovery to commercial manufacturing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AMRI overvalued or undervalued right now?
Albany Molecular Research, Inc. (AMRI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AMRI before investing?
Before investing in Albany Molecular Research, Inc. (AMRI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the provided information and may not be up-to-date.
- Competitive landscape analysis is based on available information and may not be exhaustive.
- Growth opportunities and risks are based on current market trends and company strategy and are subject to change.